8-K: Venus Concept Reduces Debt by $6.5 Million Through Equity Exchange with Madryn Amidst Ongoing Financial Restructuring

Venus Concept Inc. announced a $6.5 million debt-to-equity exchange with Madryn Health Partners, significantly reducing its outstanding debt and optimizing its capital structure while securing crucial liquidity waivers and loan extensions.

Summary

• Venus Concept Inc. entered into an Exchange Agreement with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP on June 30, 2025.
• The Company exchanged existing Secured Subordinated Convertible Notes totaling $17,015,808.33 (comprising $6,295,851.11 from Madryn and $10,719,957.22 from Madryn Cayman).
• In return, the Holders received new promissory notes totaling $11,096,478.83 ($4,105,696.60 to Madryn and $6,990,782.23 to Madryn Cayman) and 325,651 shares of Series Y Convertible Preferred Stock (120,491 to Madryn and 205,160 to Madryn Cayman).
• The Series Y Preferred Stock was priced at $19.96 per share, reflecting a calculation based on the common stock's average closing price for the five trading days preceding the agreement, multiplied by 9.0909.
• The Exchange closed on June 30, 2025, resulting in a $6.5 million debt-to-equity conversion.
• Total debt obligations were reduced by 14% from $39.7 million as of December 31, 2024, to approximately $34.3 million post-transaction.
• A Third Amended and Restated Registration Rights Agreement was executed, requiring the Company to file a shelf resale registration statement for common stock issuable upon conversion of Series Y Preferred Stock within 60 days after all Series Y Preferred Stock is converted.
• A Consent Agreement (MSLP Consent Agreement) was signed, waiving certain minimum liquidity requirements under the Main Street Priority Loan (MSPLP Loan Agreement) through July 31, 2025.
• Venus USA is permitted to apply the July 8, 2025, cash interest payment due under the MSPLP Loan Agreement to the respective outstanding principal balance of each Note.
• The Sixteenth Bridge Loan Amendment extended the maturity date of the Bridge Loan from June 30, 2025, to July 31, 2025.
• A New Notes Consent Agreement waived certain minimum liquidity requirements under the New Notes through July 31, 2025.
• The Company filed a Certificate of Amendment to its Certificate of Designations of Series Y Preferred Stock, increasing authorized shares from 1,200,000 to 1,500,000.
• The Company is required to seek shareholder approval at the next annual or special meeting to eliminate any limitations on the convertibility of the Series Y Preferred Stock under Nasdaq rules.

Sentiment

Score: 3

Explanation: While the company reduced debt, the necessity for liquidity waivers and loan extensions, coupled with the significantly lower preferred stock issuance price compared to prior rounds, indicates ongoing financial distress and a challenging operational environment. The 'transformation plan' and 'divestiture' suggest a company in a turnaround situation, which carries high risk.

Positives

• Successfully reduced outstanding debt by $6.5 million through a debt-to-equity exchange, contributing to capital structure optimization.
• Achieved a 14% reduction in total debt obligations, from $39.7 million as of December 31, 2024, to approximately $34.3 million.
• Secured waivers for certain minimum liquidity requirements under the Main Street Priority Loan and New Notes until July 31, 2025, providing short-term financial flexibility.
• Extended the maturity date of the Bridge Loan from June 30, 2025, to July 31, 2025, deferring immediate repayment obligations.
• Received continued partnership and support from Madryn Asset Management, a key lender and investor, for the Company's transformation plan.

Negatives

• The issuance of Series Y Preferred Stock at $19.96 per share is significantly lower than previous issuances to the same Holders ($60.66 in May 2024, $73.68 in September 2024, and $29.00 in March 2025), indicating a deteriorating valuation or more favorable terms for the lender.
• The need for waivers of minimum liquidity requirements and extensions of loan maturity dates suggests ongoing financial strain and liquidity challenges.
• The transaction involves an existing lender (Madryn), indicating continued reliance on current financing partners rather than attracting new external capital.
• Future dilution of common shareholders is possible upon conversion of the newly issued Series Y Preferred Stock.
• Shareholder approval is required to eliminate convertibility limitations on Series Y Preferred Stock under Nasdaq rules, introducing an element of uncertainty.

Risks

• Failure to obtain shareholder approval for eliminating convertibility limitations on Series Y Preferred Stock under Nasdaq rules could impact future conversions.
• Ongoing liquidity challenges, as indicated by the waivers of minimum liquidity requirements expiring on July 31, 2025, may necessitate further financial actions.
• Continued reliance on existing lenders for debt restructuring and extensions may limit future financing options or terms.
• Potential for significant dilution of common stock if preferred shares are converted, especially given the lower issuance price compared to prior rounds.
• General economic conditions and other risks outlined in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and subsequent Quarterly Reports on Form 10-Q.
• Risks associated with the successful closing and integration of the previously announced divestiture of the Venus Hair business.

Future Outlook

Management is focused on continuing its transformation plan, achieving sustained long-term growth and profitability, and is actively working towards closing the previously announced divestiture of the Venus Hair business.

Management Comments

• Rajiv De Silva, Chief Executive Officer: "We continue to optimize our capital structure with the completion of an additional debt exchange that reduces our overall debt balance. Madryns invaluable partnership has enabled us to have the financial flexibility to work on closing our previously announced divestiture of the Venus Hair business and continue our journey towards sustained long-term growth and profitability."
• Avinash Amin, MD, Managing Partner at Madryn Asset Management, LP: "Todays debt-to-equity exchange builds on our relationship with Venus and enables the Company to continue through its transformation plan. We support the efforts by the Management team and look forward to the Companys return to growth."

Industry Context

The announcement reflects Venus Concept's ongoing efforts to stabilize its financial position within the medical aesthetic technology and hair restoration industries. The focus on debt reduction and capital structure optimization suggests a strategic pivot towards financial health, which is critical in a competitive and capital-intensive sector. The mention of a 'transformation plan' and 'divestiture' indicates a broader restructuring trend, common among companies seeking to streamline operations and focus on core profitable segments in evolving markets.

Comparison to Industry Standards

• The Series Y Preferred Stock issuance price of $19.96 per share is notably lower than prior issuances to the same investors (e.g., $60.66 in May 2024, $73.68 in September 2024, $29.00 in March 2025). This downward trend in preferred stock pricing suggests a less favorable valuation for the company in this latest financing round compared to its own historical performance, which could be a red flag when compared to stable or growing companies in the medical aesthetics sector like InMode Ltd. (INMD) or Cutera, Inc. (CUTR) that might secure financing on more advantageous terms.
• The need for waivers of minimum liquidity requirements and extensions of loan maturity dates (e.g., Bridge Loan extended from June 30, 2025, to July 31, 2025) indicates a strained liquidity position. This contrasts with industry leaders who typically maintain robust cash reserves or access to credit lines without requiring such frequent waivers or extensions, suggesting Venus Concept is operating closer to its financial limits than peers.

Corporate Governance

Related Party Transactions

• The debt-to-equity exchange and related agreements were entered into with Madryn Health Partners, LP and Madryn Health Partners (Cayman Master), LP, who are existing lenders and investors (classified as 'Permitted Holders').
• The new notes and consent agreements continue the financial relationship with Madryn, indicating ongoing reliance on this specific financing partner.

Stakeholder Impact

• Shareholders: Face potential dilution from the conversion of Series Y Preferred Stock into common stock, especially given the lower issuance price compared to prior rounds. Their approval is required for full convertibility of the preferred shares.
• Creditors (Madryn): Converted a portion of their debt into preferred equity, received new notes, and granted waivers/extensions, indicating a restructuring to support the company's financial stability.
• Employees/Management: The new notes include a covenant requiring Rajiv De Silva (CEO) to maintain his position, with a replacement acceptable to the Holder needed within 90 days if he voluntarily terminates, suggesting stability in key leadership is important to lenders.

Next Steps

• Company to include a proposal in proxy materials for the next annual or special shareholder meeting to eliminate limitations on the convertibility of Series Y Preferred Stock under Nasdaq rules.
• Company to file a shelf resale registration statement with the SEC within 60 days following the conversion of all issued and outstanding Series Y Preferred Stock into Common Stock.
• Company is working on closing the previously announced divestiture of the Venus Hair business.

Key Dates

Recommendation

Keywords

Venus Concept, VERO, debt-to-equity exchange, convertible notes, preferred stock, capital structure, debt reduction, Madryn Asset Management, liquidity waiver, loan extension, Nasdaq compliance, shareholder approval, SEC filing, corporate finance, financial restructuring